Autosomal recessive spastic ataxia

Autosomal recessive spastic ataxia (ARSA, Orphanet code 316240) is a broad clinical grouping encompassing a set of rare inherited neurological disorders characterized by the combination of spasticity (abnormal muscle stiffness and tightness, particularly in the lower limbs) and cerebellar ataxia (impaired coordination and balance due to cerebellar dysfunction). These conditions primarily affect the central nervous system, including the corticospinal tracts (which control voluntary movement) and the cerebellum (which coordinates balance and fine motor control). Patients typically present with progressive difficulty walking, lower limb stiffness, unsteady gait, and impaired coordination of movements. Additional features may include dysarthria (slurred speech), eye movement abnormalities such as nystagmus, peripheral neuropathy, and in some subtypes, cognitive impairment or other systemic manifestations. This category includes several distinct genetic subtypes, each caused by mutations in different genes. Well-known forms include spastic ataxia of Charlevoix-Saguenay (ARSACS, caused by SACS gene mutations), autosomal recessive spastic ataxia with leukoencephalopathy (caused by MARS2 or other gene mutations), and other rarer subtypes. The age of onset, severity, and progression vary depending on the specific genetic subtype. Some forms present in early childhood with delayed motor milestones, while others may not become apparent until adolescence or adulthood. There is currently no cure for autosomal recessive spastic ataxias. Treatment is supportive and symptomatic, focusing on physical therapy and rehabilitation to maintain mobility and function, antispasticity medications (such as baclofen or tizanidine) to manage muscle stiffness, speech therapy for dysarthria, and occupational therapy to assist with daily activities. Orthopedic interventions may be needed for skeletal deformities. Genetic counseling is recommended for affected families. Research into disease-modifying therapies is ongoing but no specific targeted treatments have been approved to date.

Common questions about Autosomal recessive spastic ataxia